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Although the association of angiotensin I-converting enzyme
inhibitors (ACEis) with a negatively charged membrane is
thought to be responsible for hypersensitivity reactions (HSRs)
during hemodialysis, we hypothesize that these complications
are due to changes in plasma aminopeptidase P (APP) activity
and genotype. To test this hypothesis, we measured plasma
APP activity in 14 patients who suffered HSR (HSRþ ) while
dialyzed with an AN69 membrane and simultaneously treated
with an ACEi. APP activity was also studied in a control group
(n¼ 39) dialyzed under the same conditions, but who did not
suffer any side effect (HSR). We found significantly decreased
plasma APP activity (P¼ 0.013) in HSRþ subjects as well as
altered degradation of endogenous des-Arginine9-bradykinin,
with a significantly lower b value (Po0.001). The same
analytical approach was taken in 171 relatives of HSRþ
patients. Variance component analysis suggested that genetic
differences may explain 61% of the phenotypic variability of
plasma APP activity (Po0.001) and the kinetic parameters that
characterized kinin degradation. We also showed that the
C-2399A single-nucleotide polymorphism at the XPNPEP2
locus was a significant predictor of APP activity in the
39 HSR controls (P¼ 0.029). Furthermore, a recessive genetic
model for the A allele disclosed a significant difference in mean
APP activity by genotype (Po0.001). Finally, our study defined
the nonspecific inhibition of recombinant APP by some ACEis.
In conclusion, this paper highlights the complexity of HSR in
hemodialysis, suggesting, as with angioedema, that these rare,
but life-threatening adverse events are governed by several
metabolic and genetic factors.
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Although beneficial in the treatment of various cardio-
vascular disorders and the progression of renal failure in
diabetic and non-diabetic patients,1,2 angiotensin I-convert-
ing enzyme inhibitors (ACEis) are associated with several side
effects, for which symptoms largely depend on the clinical
context. Hypersensitivity reactions (HSRs) or anaphylactoid
reactions, which mimic symptoms of immediate hyper-
sensitivity, are observed in patients chronically hemodialyzed
with synthetic, highly permeable, electronegative membranes
while taking ACEi.3 These reactions typically occur in the
first minutes of the dialysis session, and their intensity is
usually mild to moderate, but may be life-threatening.
Numerous factors have been hypothesized to cause HSR.4–7
However, reported increases in plasma bradykinin (BK)
during episodes of HSR8–10 in hemodialyzed patients suggest
a role of kinins in the genesis of these adverse reactions.
The nonapeptide BK is released from high molecular
weight kininogen by plasma kallikrein during activation
of the contact system. It is subsequently metabolized,
mainly by three zinc metallopeptidases.11,12 ACE and X-
Pro-aminopeptidase (aminopeptidase P (APP)) are the first
and second inactivating metallopeptidases of BK, respectively.
Carboxypeptidase N transforms BK into its carboxytruncated
active metabolite, des-Arginine9-BK (des-Arg9-BK), which
constitutes minor metabolic pathway unless ACE is inhibited.
Des-Arg9-BK is also degraded by ACE and APP. In this case,
however, APP represents the main peptidase activity whereas
ACE plays a secondary role.
BK exerts its pharmacological activities through its
constitutively expressed kinin B2 receptor,
13 although
des-Arg9-BK binds to the B1 receptor, the synthesis of
which is increased by different cytokines.14 Both B1 and B2
receptor agonists have several physiological activities13
including the ability to dilate the peripheral vasculature,
directly and indirectly (resulting in hypotension), constrict
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the pulmonary airways (evoking bronchospasms), and
induce the release of histamine from mast cells, which are
hallmarks of HSR.
Human APP, a hydrolase that cleaves N-terminal imido
bonds normally protected from attack by other known
aminopeptidases, exists in two known forms: a glycosylpho-
sphatidylinositol-anchored membrane form (hmAPP) and
a cytosolic form (hcAPP). mRNA of both APP forms have
been found in different tissues.15 We previously reported
significantly lower plasma APP activity in patients who
suffered ACEi-linked acute side effects.16–20 When ACE was
inhibited, the low APP activity was associated with an
increased half-life of exogenously added16 or endogenously
generated des-Arg9-BK.19,20
We reported recently21 that genetic factors partially
regulated the activity of APP in eight families, each with
one member who developed ACEi-associated angioedema
(AE). Heritability of plasma APP activity was estimated to
be 34% (725%). Sequencing the upstream region of
the XPNPEP2 gene coding for hmAPP, we found a single-
nucleotide polymorphism (SNP) C-2399A, for which
the A allele was linked with low plasma APP activity. In
addition, we observed a deletion of 175 bp in one case
of AE. This deletion resulted in a truncated protein of
38 amino acids.21
In the present study, we tested the hypothesis that HSR
may occur not only from the association of a negatively
charged membrane (physicochemical factor) and an ACEi
(pharmacological agent), but is also dependent on the ability
(metabolic aspect) of the dialyzed patient to degrade kinins,
generated from activation of the contact system of plasma.
We measured APP activity, and defined the metabolism of the
endogenous kinins BK and des-Arg9-BK in the plasma of 14
patients who suffered HSR (HSRþ ) while dialyzed with an
AN69 membrane and simultaneously treated with an ACEi.
These same parameters were also measured in 171 relatives of
these HSRþ patients and a control group (n¼ 39) dialyzed
under the same conditions, but who did not suffer any side
effect (HSR). Furthermore, we calculated the importance of
heritability on APP activity, and investigated kinetic para-
meters among the families of HSRþ patients. Finally, we
tested the nonspecific inhibition of different ACEi on a
recombinant wild-type form of hmAPP.22
RESULTS
Metabolic investigations
APP activity in plasma. APP values of the HSRþ patients
and their relatives appear in Figure 1. Figure 2 presents
the distribution of APP activity in both groups of dialyzed
patients compared to that of the reference population.12,22
Mean activity (827107 U) in HSRþ plasma was signifi-
cantly lower than in HSR (1937199 U, P¼ 0.013) and the
reference samples (3177248 U, P¼ 0.000). Mean plasma
APP activity in the dialyzed patients corresponded respec-
tively to the 11th (HSRþ ) and 38th percentile (HSR) of
the reference population. In the HSR group, there was
no significant difference in mean APP values in diabetic
patients compared to other kidney diseases (P¼ 0.516).
Similar results were obtained between diabetes and glomer-
ular diseases (P¼ 0.689), diabetes, and interstitial nephritis
(P¼ 0.074) (Table 1).
Metabolism of endogenous BK and des-Arg9-BK in plasma.
Figure 3 illustrates the mean metabolic profiles of BK
and des-Arg9-BK during the activation of HSRþ and
HSR plasma in the presence of an ACEi. No discrepancy
in BK was detected for the different kinetic parameters
(Table 2), except for a lower a among HSRþ patients
(P¼ 0.043), which characterized BK generation from high
molecular weight kininogen. The main metabolic difference
between HSRþ and HSR patients occurred in des-Arg9-
BK degradation. In the HSRþ group, a lower b value
(Po0.001) reflected the altered degradation of this B1
receptor agonist by APP in the presence of an ACEi. The
des-Arg9-BK degradation anomaly was responsible for a
higher maximal concentration of the peptide (P¼ 0.048)
during the activation period. When Benjamini’s correction23
for multiple comparison was applied to these kinetic
parameters, two independent of APP activity became
nonsignificant (a for BK, P¼ 0.371; t1/2 slope of formation
(P¼ 0.093) of des-Arg9-BK).
Genetic investigations
Heritability estimates. In members of the 14 families of
HSRþ patients, heritability of APP was estimated at 0.61
(70.18), indicating that genetic factors may explain 61% of
the phenotypic variability in plasma APP activity (Po0.001).
This significant heritability estimate involved the kinetic
parameters, which characterized the degradation of BK and
des-Arg9-BK, and depended mainly on APP activity when
ACE was inhibited (Table 3). In such cases, the P-values
obtained by Benjamini’s correction did not affect the
heritability estimates.
Genotyping. The genotyping results of C-2399A SNP of
the XPNPEP2 gene in HSRþ and HSR patients are
presented in Table 4. The SNP was found to be a significant
predictor of APP activity in the 39 HSR controls (A and
AA: 070, CA: 2517167, C and CC: 2227206 pmol
K(Dnp)PPGK(Abz) hydrolyzed/min/ml; analysis of variance:
P¼ 0.029). Linear contrast on the genotyped groups was
significant (P¼ 0.012). Furthermore, a recessive genetic
model for the A allele disclosed a significant difference in
mean APP activity by genotype (A and AA: 070; CA and C
and CC: 2287197 pmol K(Dnp)PPGK(Abz) hydrolyzed/
min/ml; t-test: Po0.001). However, the SNP was not
found to be predictive of HSR status as the association
between groups (HSRþ and HSR) and genotypes was not
significant (Fisher’s exact test: P¼ 0.4289).
Pharmacological investigations
Inhibition studies of recombinant APP with metallopeptidase
inhibitors. The effect of various inhibitors on the hydrolysis
of K(Dnp)PPGK(Abz)NH2 by a recombinant soluble hmAPP
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is illustrated in Figure 4. The selective APP inhibitor apstatin
and the sulfhydryl group-containing captopril were the most
potent inhibitors (IC50 of 0.671.1 and 1771.1 mM, respec-
tively). The other ACEi tested only inhibited at higher
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Figure 1 | Cohorts ascertained for linkage analysis. One member of each kindred (the propositus), depicted in black, developed HSR
associated with ACEi therapy. Willing participants are depicted in white. Non-participants are shaded. The SNP genotype and the APP activity
are indicated for each member of the different families. SNP genotypes were not available for family XIII.
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Figure 2 | Distribution of APP activities. Distribution of APP activities
in HSRþ and HSR patients compared with the reference population.
*P¼ 0.013 HSRþ vs HSR; wP¼ 0.000 HSRþ vs reference.
Table 1 | Main clinical characteristics of patients who
presented HSRs during hemodialysis (HSR+) and those
without (HSR), while treated with ACEi
Variable HSR+ HSR–
Number 14 39
M/F 5/9 21/18
Age (extremes) 50 (29–71) 53 (24–78)
Time on dialysis (months) 38.4716.8 54.0721.6
Diabetes type 2 1 12
Nephroangiosclerosis 2 5
Glomerular disease 7 7
Chronic interstitial disease 2 5
Polycystic disease 1 5
Unknown 1 5
ACEi, angiotensin I-converting enzyme inhibitor; F, female; HSR, hypersensitivity
reaction; M, male.
Values are mean7s.d.
All dialyzers were equipped with the AN69 membrane and ACEi was prescribed for
more than 1 month.
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concentrations (mM ranges for enalapril) or not at all
(lisinopril and ramipril).
DISCUSSION
HRS were rare in the 1980s, but this incidence increased
significantly during the 1990s owing to the widespread use of
ACEi in patients dialyzed with a negatively charged
membrane.24 This association prompted a warning from
American federal agencies.25
As other rare acute side effects of ACEi, HSR could
happen when at least three different factors are present
(Figure 5). The first one is the presence of a drug that in-
hibits specifically ACE but could also nonspecifically inhibit
another metallopeptidase as APP involved in the meta-
bolism of kinins. The second factor may be the negatively
charged membranes which is the physicochemical trigger
for the release of kinins. The third factor is a metabolic
factor which is at least in part genetically regulated. It
characterizes the capacity of the dialysed patient to
metabolize kinins once ACE is inhibited. In this paper, we
have explored the metabolic and the genetic aspect of the AR.
We have also evidenced a nonspecific inhibition of APP by
some ACEi.
Despite the recent reduction of HSR incidence owing to
decreased membrane surface electronegativity, there is still a
persistent risk of this severe adverse reaction during
hemodialysis, especially among patients taking an ACEi. As
the triggering factor (Z potential of the membrane)
contributing to HSR is already known, the metabolic factors
predisposing to it have yet to be fully understood. In this
report, we address questions concerning the factors that
control the metabolism of kinins in the presence of an ACEi.
In this case, the metabolism of kinins (mainly of the b1
receptor agonist) depends on APP activity.
Although the nature of the isoform (hmAPP, hcAPP, or
both) responsible for plasma APP activity remains unknown,
we recently published the analysis of a genome-wide
microsatellite scan, which yielded highly significant linkage
between plasma APP activity and a marker flanking the
XPNPEP2 gene encoding hmAPP. Linkage was not obtained
for hcAPP.21 This suggests that APP activity in plasma is
mainly or uniquely the result of hmAPP. hmAPP is mainly
localized on the external site of the plasma membrane of
endothelial cells, on the brush border membrane of epithelial
cells in the intestine, and in renal proximal tubules.15 hmAPP
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Figure 3 | Metabolism of endogenous BK and des-Arg9-BK. Mean
kinetic g model-fitted profiles of formation and degradation of (a) BK
and (b) des-Arg9-BK for HSRþ (straight line) and HSR (dashed line)
patients after activation of the contact system with glass beads in the
presence of enalapril.
Table 2 | Parameters characterizing the c model fitted to kinetic parameters of endogenous kinins
BK des-Arg9-BK
Parameter HSR HSR+ HSR HSR+
Alpha (a) 0.8170.20 0.6970.18 0.8770.30 0.7070.16
P=0.043 P=0.011
Formation t½ (min) 1.3070.39 1.1570.52 6.5475.88 7.7976.83
P=0.247 P=0.526
Formation t½ slope 14 34974163 18 747711 041 4517202 7377413
P=0.168 P=0.031
Maximum (nM) 5237137 5597101 79746 2397275
P=0.375 P=0.048
Time of maximum (min) 7.171.4 7.372.1 39747 1127239
P=0.780 P=0.275
Beta (b) 0.1270.04 0.1070.04 0.0470.02 0.0270.01
P=0.168 Po0.001
Degradation t½ (min) 21.375.2 23.576.5 1077106 1607124
P=0.218 P=0.128
Degradation t½ slope 21697841 210771 101 74743 80758
P=0.829 P=0.675
AUC (pmol/ml min) 11.8E374.5E3 14.0E374.70E3 16.5E3740.5E3 31.6E471.04E6
P=0.135 P=0.300
AUC, area under the curve; BK, bradykinin; des-Arg9-BK, des-Argin-ine9-BK; HSR, hypersensitivity reaction.
Values are means7s.d.
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has also been found in human heart preparations where it
contributes to BK metabolism.26 It has been hypothesized
that hmAPP on endothelial cells inactivates BK and locally
produced des-Arg9-BK. Suppression of hmAPP activity by
apstatin, a commercially-available inhibitor, has highlighted
the pathophysiological role of this metallopeptidase. How-
ever, the pharmacological effect of its blockade becomes
evident mainly in the presence of an ACEi. In fact, inhibition
of APP in rats synergizes the hypotensive action of injected
BK, but this hypotension-potentiating influence is mostly
seen in the presence of lisinopril.27 In humans, apstatin has
no effect on the inflammatory reaction induced by local
subcutaneous BK injection in the forearm. However, the APP
inhibitor acts synergistically with quinapril to augment the
wheal response to exogenous BK.28
In this study, we measured APP activity in the plasma of
HSR, HSRþ , and their relatives. For this purpose, we used
the newly described, internally quenched fluorescent sub-
strate K(Dnp)PPGK(Abz). This substrate, which mimics the
NH2-terminal sequence of the physiological substrate BK/
des-Arg9-BK, is highly specific for APP activity.22
With plasma samples obtained from the reference
population,12 we demonstrated that APP activity measured
according this new analytical approach, was not only
correlated with that published previously with the Arg-Pro-
Pro (RPP) substrate (r¼ 0.921, Po0.001), but also exhibited
a higher correlation with the degradation rate of des-Arg9-BK
in the presence of an ACEi (r¼ 0.822, Po0.001).22 With this
new substrate, we found significantly lower APP activity in
HSRþ compared to both HSR dialyzed patients and the
reference population.
As in our previous reports involving AE patients, the
metabolic profiles of endogenous BK and des-Arg9-BK in
Table 3 | Heritability analysis of kinetic parameters for the kinins BK and des-Arg9-BK with SOLAR
BK des-Arg9-BK
Parameter Heritability Error Probability Heritability Error Probability
Alpha (a) 0.08 0.112 0.220 0.10 0.099 0.113
Formation t½ (min) 0.19 0.136 0.043 0.29 0.132 0.004
Formation t½ slope 0.21 0.108 0.009 0.37 0.145 o0.001
Maximum (nM) 0.33 0.127 o0.001 0.51 0.150 o0.001
Time of maximum (min) 0.50 0.156 o0.001 0.24 0.155 0.035
Beta (b) 0.35 0.138 0.001 0.36 0.131 o0.001
Degradation t½ (min) 0.56 0.147 o0.001 0.22 0.153 0.051
Degradation t½ slope 0.34 0.126 o0.001 0.39 0.151 o0.001
AUC (pmol/ml min) 0.30 0.149 0.008 0.34 0.159 0.005
AUC, area under the curve; BK, bradykinin; des-Arg9-BK, des-Argin-ine9-BK; SOLAR, Sequential Oligogenic Linkage Analysis Routines.
Table 4 | Genotype distribution of the XPNPEP2 C-2399A
polymorphism in HSR+ and HSR patients
A and AA CA C and CC Total
HSR+ 4 2 7 13
HSR 6 7 26 39
Total 10 9 33 52
HSR, hypersensitivity reaction.
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Figure 4 | Specific and nonspecific inhibition of human recombi-
nant soluble membrane APP. Effect of increasing concentrations of
various inhibitors on recombinant soluble hmAPP-catalyzed hydro-
lysis of K(Dnp)PPGK(Abz)NH2 as described in Materials and Methods.
The data were plotted to fit the one-site competition equation by
nonlinear regression with GraphPad software and imposed con-
straints (5.0 to 110% activities). IC50 obtained were 0.671.1 mM for
apstatin (APS), 1771.1mM for captopril (CAP), and over 1 mM for
enalapril (ENA). Curves for lisinopril (LIS) and ramipril (RAM) did not
converge (no inhibition).
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Figure 5 | Hypothesis for a multifactorial nature of the HSR in
hemodialysis. HSR results from the meeting of at least three
different factors: a physicochemical factor triggers the contact system
of plasma and liberates BK, a pharmacological agent inhibits ACE
activity, and a metabolic aspect which characterizes the capacity of
the patient to metabolize kinins.
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HSRþ plasma were obtained by activating the contact
system with glass beads in the presence of an ACEi.
This mimics what happens in vivo when the plasma of an
ACEi-treated patient comes in contact with a negatively
charged membrane at the beginning of hemodialysis.
Under our experimental conditions, we did not obtain
evidence of any anomaly in the metabolism of the
nonapeptide BK. Abnormal breakdown of des-Arg9-BK,
assessed by significant differences in the b parameter that
depended only on APP activity, led to a significant increase
of maximal peptide concentration during the in vitro
incubation period.
Similar metabolic anomalies among ACEi patients who
developed HSRþ or AE indicate that one or several common
genetic predisposition(s) may partially explain the patho-
physiology of both adverse reactions. In the 14 families of
HSRþ patients, we obtained heritability estimates for APP
activity that were even higher than those calculated
previously for AE.21 This may be explained by different
factors: the number of families (14 vs 8), the new analytical
approach, but also the difference in the clinical context of
side effects. We also found a significant association between
low levels of APP activity (and the capacity to degrade des-
Arg9-BK) and the C-2399A SNP polymorphism in the
XPNPEP2 gene identified previously,21 lending further
credence to concepts that genetics, most commonly SNPs
as candidate gene factors, determine interindividual varia-
bility in risk for the disease.29 The C-2399A polymorphism
was found to be predictive of low APP activity, but not
sufficient for phenotype characterization, as is usually the
case for quantitative traits.
As early as 1992, Hooper et al.30 reported that several
ACEi inhibit APP purified from the pig kidney. Given this,
we could not exclude that an ACEi nonspecifically inhibited
APP activity among HSRþ patients. This was particularly
true in dialyzed patients with impaired renal excretion of
most ACEi. We showed that, in addition to the selective
APP inhibitor apstatin, the sulfhydryl-containing ACEi
captopril could also inhibit APP at mM concentrations.
Captopril was the first ACEi to be used clinically. It is
characterized by a relatively weak inhibition constant
(Ki¼1700 vs 200 and 7 pM for enalapril and ramipril,
respectively) and short half-life, necessitating multiple daily
takes, at higher dosages, to achieve clinical efficacy. The
concentration of captopril and other ACEi has not been
documented in the plasma of dialyzed patients at the time of
HSR episodes. Nevertheless, it is conceivable that, under
these conditions, the high plasma concentrations needed to
therapeutically inhibit ACE, coupled with poor clearance in
dialyzed patients, could lead to the nonspecific inhibition of
other metallopeptidases, such as APP, resulting in the
accumulation of the B1 agonist.
This nonspecific inhibition of APP by captopril and the
important proportion of patients treated with the ACEi in
the HSRþ group (8/14 vs 0/39 in HSR) could plead for its
role in the pathophysiology of some HSRs. Among the eight
HSRþ patients treated by this ACEi at the time of the
HSRþ episode, six had low or undetectable APP activity, but
two (propositus of family X and XI) had activity (268 and
337 U, respectively) equal to or higher than the 50th
percentile of the reference population. We could then
hypothesize that APP activity could have been inhibited in
vivo by captopril at the time of the HSR episode.
This study highlights the complexity of HSR, as is the case
with AE and other side effects of metallopeptidase inhibitors
(ACEis and vasopeptidase inhibitors). These observations
also raise important questions about the regulation of APP
enzymatic activity in human plasma, and, ultimately, about
the pharmacological activity of B1 agonists in humans, and
particularly in dialyzed patients. The factors that regulate
plasma APP activity are not known and must be identified.
Plasma APP activity is regulated at least two different
levels. First, at the level of synthesis in cells by yet
unidentified transcriptional and possibly post-transcriptional
mechanisms responsible for the quantity of APP bound at
the cell surface by a glycosylphosphatidylinositol anchor.
Studies are now ongoing in our laboratory, using cells
expressing APP, such as endothelial cells and human
embryonic kidney cells (HEK 293 cells), to better characterize
these mechanisms. The second level at which plasma APP
activity is controlled is at cleavage of the glycosylpho-
sphatidylinositol anchor and release of the protein in
plasma. Phospholipase C has been shown to be a candidate
for such release. More interesting, however, is the recent
report that ACE has glycosylphosphatidylinositolase
activity.31 As both APP and ACE are often expressed in the
same cells, it will be interesting to see whether ACE levels
affect membrane-bound APP.
Our study also raises a question about the pathophysio-
logical meaning of our in vitro observations: the con-
sequences in vivo of B1 agonist accumulation during
activation of the contact system of plasma in the presence
of an ACEi. In a rat model, we have previously demonstrated
a pro-inflammatory effect of des-Arg9-BK when its corre-
sponding B1 receptor is expressed.
32 More recently, we have
also observed in the pig that chronic enalapril treatment
induces B1 receptors in the kidneys.
33 However and contrarily
to BK,10,34 no des-Arg9-BK concentrations have been
reported until now in human and particularly in plasma
of dialyzed patients. The present results could be used as
a basis for a clinical study in which plasma BK and
des-Arg9-BK concentrations will be documented in HSRþ
and HSR patients. The association of these circulating
levels of both B1 and B2 agonists with the clinical symptoms
and the inflammatory status of these patients could
elucidate the relative role of B1 and B2 receptors in these
rare but potentially serious side effects. These results could
also help us to understand the regulation of B1 receptor
expression in dialyzed patients and could objectivate
the usefulness of non-peptidic B1 antagonists, now in
clinical development, for the treatment of metallopeptidase
inhibitor side effects.32,33
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MATERIALS AND METHODS
Participants
The study protocol was conducted according to French regulations
and was approved by Ethics Committees from the Centre hospitalier
de l’Universite´ de Montre´al (CHUM), the Institut de cardiologie de
Montre´al, McGill University, and the Universite´ de Rennes (France).
Informed consent was obtained from all participants. Patients were
from five different nephrology-hemodialysis centers in France
(Hoˆpital Universitaire and ARPDD, Reims, Centre Hospitalier La
Beauche´e, Saint-Brieuc, Centre Hospitalier Louis-Pasteur, Cher-
bourg, Centre Hospitalier Intercommunal de Cornouaille, Quim-
per) and one in Canada (Hoˆtel-Dieu de Saint Je´roˆme, Que´bec).
Sampling took place at these sites between July 2001 and December
2003. Fifty-three patients on chronic hemodialysis, 39 HSR and 14
HSRþ , were enrolled in this study. Their main clinical character-
istics are shown in Table 1. In addition, 171 relatives of the 14
HSRþ patients participated in a medical interview and donated
blood samples for genetic linkage research (Figure 1).
Hemodialysis
All patients were chronically hemodialyzed three times per week,
for average session duration of 240 min. In all instances, the
dialyzer, either flat sheet or hollow fiber, was equipped with
the AN69 polyacrylonitrile membrane (Gambro-Hospal, Meyzieux,
Lyon, France). The blood flow rate comprised between 250
and 350 ml/min. Unfractionated heparin was used as anticoagulant.
The dialysate contained bicarbonate and was of the highest
bacterial and endotoxin quality. Adequacy of dialysis was assessed
by Kt/V for urea higher than 1.2. Dialyzers were not reused. In
those patients who developed HRS, ACEi was withdrawn, and
they were shifted to another type of membrane, that is, a neutral
membrane.
Hypersensitivity reaction
The presence of HSR was defined on the basis of clinical criteria
proposed recently by Bright et al.35 in a survey of HSR ‘as an
incident involving two or more of the following symptoms
occurring within 5–20 min of starting dialysis: abdominal cramps,
nausea, vomiting or diarrhea; shortness of breath, chest tightness,
wheezing, or bronchospasms; facial, labial and/or lingual swelling,
AE or laryngeal edema; hypotension (420 mmHg drop in systolic
blood pressure); flushing, or warmth; numbness or tingling of the
fingers, toes, lips, or tongue’. All the symptoms disappeared in 2–6 h
after the end of dialysis, whether the session was completed or
interrupted.
Dialyzed patients who presented HSR (HSRþ group) and their
pedigree are represented in Figure 1. The etiology of renal failure
was diabetes mellitus (n¼ 1, propositus of family II); glomerular
disease (n¼ 7, propositus of family I, III, IV, V, VI, VIII, XIV);
chronic interstitial nephritis (n¼ 2, propositus of family VII, X);
nephroangiosclerosis (n¼ 2, propositus of family XI, XIII); poly-
cystic renal disease (n¼ 1, propositus of family IX); and unknown
(n¼ 1, propositus of family XII).
At the time of the HSR episode, eight patients were treated with
captopril (propositus of family I, II, V, VI, IX, X, XI and XIV), four
with enalapril (propositus of family VII, VIII, XII, XIII), one with
benazepril (propositus of family V), and one with lisinopril
(propositus of family III).
The group of patients who never presented any side effect while
dialyzed in the same conditions as HSRþ served as the control
group (HSR patients). At the time of blood sampling, these
patients were treated with the following ACEi: ramipril (n¼ 24),
enalapril (n¼ 5), perindopril (n¼ 7), and fozinopril (n¼ 3).
Laboratory investigations
Blood and plasma samples. Venous blood was sampled at the
start of dialysis and before heparin administration. Blood was
collected in BD Vacutainers either on Na-citrate (1/10 v/v) for
metabolic investigations or on K2-ethylenediaminetetraacetic acid
for DNA analysis. Citrated blood was centrifuged at 2000 g, plasma
was collected and stored in sealed tubes at 801C before shipping to
the reference center. K2-ethylenediaminetetraacetic acid samples
were stored at room temperature until DNA extraction.
Reagents. The ACEi enalapril was from Merck Frosst Canada
(Kirkland, Que´bec, Canada); the ACEi ramipril was a generous gift
from Dr W Linz (Sanofi Synthelabo-Aventis GmbH, Germany); BK
and des-Arg9-BK were acquired from Peninsula Laboratories
(Belmont, CA, USA); the internally quenched fluorescent substrate
K(Dnp)PPGK(Abz)22 was synthetized by Professor A Carmona
(Department of Biophysics, Escola Paulista de Medicina, UNIFESP,
Sa˜o Paulo, Brazil). All other fine chemicals and inhibitors were from
Sigma (Montreal, Que´bec, Canada).
Metabolic investigations
Measurement of APP enzymatic activity in plasma. APP
activity was assessed kinetically using the K(Dnp)PPGK(Abz)
quenched fluorescent substrate. This original method was developed
and validated recently in our lab.22 The substrate allows sensitive
kinetic measurement of plasma APP activity with intra- and inter-
assay coefficient of variation (CV)% equal to 6 and 10%,
respectively.22 One unit of APP activity corresponds to 1 pmol of
K(Dnp)PPGK(Abz) hydrolyzed per min/ml.
This analytical approach has the advantages of kinetic measure-
ment of enzyme activity, and similar affinity of the enzyme for the
new substrate (Km: 2075 mM) when compared to its natural
substrate, des-Arg9-BK (Km: 56713 mM);
22 it contrasts with values
for the synthetic tripeptide Arg-Pro-Pro (Km: 837775mM) pre-
viously employed to assess APP activity.
Metabolism of endogenous BK and des-Arg9-BK in plasma
Contact system activation. Plasma was activated as described
earlier for a group of normal healthy people12 and AE patients.19
Briefly, 1 ml of plasma was preincubated with enalapril for 20 min at
371C in polypropylene tubes at a concentration (130 nM) which
totally inhibited ACE activity. The contact system was then activated
by incubation of the plasma with glass beads (371C, with agitation).
The reaction was stopped after various incubation periods
(0–60 min) by adding cold anhydrous ethanol at a final concentra-
tion of 80% vol/vol. The samples were then incubated at 41C for 1 h
and centrifuged (41C, 15 min, 3000 g) for the complete precipitation
of protein. The supernatant was decanted and evaporated to dryness
in a Speed Vac Concentrator (Savant, Farmingdale, NY, USA) before
quantification of the immunoreactive peptides BK and des-Arg9-BK.
Measurement of immunoreactive BK and des-Arg9-BK. The
residues of evaporated ethanolic extracts were resuspended in 50 mM
Tris/HCl buffer (pH 7.4) containing 100 mM NaCl and 0.05% Tween-
20. After resuspension, residual BK and formed des-Arg9-BK were
quantified by two specific competitive enzyme immunoassays.36,37
Briefly, both immunoassays use purified polyclonal immunoglo-
bulin G raised against the C-terminal portion of the peptides,
responsible for the B1 or the B2 pharmacological activities.
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Antibodies were raised in rabbits against the C-terminal part of
BK covalently linked to bovine serum albumin using glutaraldehyde.
The tracer used was BK labeled with digoxigenin-3-O-methylcar-
boxyl-e-aminocaproic acid-N-succinimide ester (DIG-O-Su,
Roche diagnostic, Laval, Que´bec, Canada) purified by high-pressure
liquid chromatography and characterized by mass spectrometry
and radioimmunoassay. Kallidin (Lys-BK) and BK are 100%
crossreactive with these antibodies. None of the BK metabolites
(des-Arg9-BK or Lys-des-Arg9-BK) present a significant cross-
reactivity (o1%) with the anti-BK antibodies. The calibra-
tion curve was characterized by an ED50 of 7.37 pg/well (50 ml).
The CV for each value of the calibration curve is less than 5%.
Intra- and inter-assay CV of BK measurements were lower than 4.0
and 7.4%.
For the quantification of des-Arg9-BK, polyclonal antibodies
were generated in rabbit against Cys-Lys-Aca-Lys-des-Arg9-BK
coupled with maleimide-activated keyhole Limpet Hemocyanin
and purified by gel filtration (PD-10). The tracer was obtained
by coupling des-Arg9-BK to DIG-O-Su. After purification by
hydrophobic chromatography, the tracer was also characterized
by mass spectrometry and radioimmunoassay. Lys-des-Arg9-BK
and des-Arg9-BK exhibit identical 100% immunoreactivity for the
C-terminal peptide-specific antibodies. Neither BK nor Lys-BK
crossreact in the assay and different metabolites of kinins present
less than 0.1% cross reactivity. The calibration curve is characterized
by an ED50 of 6.96 pg/well (50 ml). The CV for each value of the
calibration curve is less than 6%. The intra-assay CV calculated at
three concentration levels varies between 5 and 8%, and the inter-
assay CV is lower than 10%. The bound DIG-BK/DIG-des-Arg9-BK
is reacted with anti-DIG Fab labeled with horseradish peroxidase.
The reaction was revealed by adding o-phenylenediamine and read
by absorbance at 530 nm.
Mathematical treatment of the kinetic profiles of BK and des-
Arg9-BK. The following mathematical model y¼ k ta ebt, t40
was fitted to the concentrations of endogenous BK and des-Arg9-BK,
measured at different times (t) for each plasma sample. This three-
parameter (k, a, and b; k40, a, and bX0) model corresponds to a
form similar to g distribution,38 and has been described and
validated earlier.12 The a and b parameters are respectively related to
the shape of the first and the second part of the curve,
corresponding to the formation and the degradation of each
peptide. These a and b parameters allow the calculation of other
kinetic parameters: time of the maximum: the value of t for which
the maximum of the curve was obtained: t¼ a/b; maximum: the
value of the maximum of the curve which corresponds to the value
of the curve for t¼ a/b; AUC: the area under the curve which is
mathematically given by kG(aþ 1)/baþ 1, where G(aþ 1) is the g
function; half-life of formation (tf): the value tf in the interval 0 to a/
b for which ta ebt¼ (0.5) (a/b)a ea; half-life of degradation (td):
the value td in the interval a/b toN for which t
a ebt¼ (0.5) (a/b)a
ea; slope of the half-life of formation: the value of the slope
of the curve at half-life formation¼ kebtff ta1f ða btf Þ; and slope of
the half-life of degradation: the value of the slope of the curve at
half-life degradation: kebtdd t
a1
d ða btdÞ.
Genetic investigations
Heritability. To test the hypothesis that genetic factors could
influence the variability of APP activity and of kinetic parameter
values for the metabolism of BK and des-Arg9-BK, heritability was
estimated among the combined families of the 14 HSRþ patients.
For this analysis, probands were not excluded on the basis that the
pedigrees were not selected for APP activity levels and covariates
were not included in the analysis.
Genotyping. A commercially available protocol (Gentra, Min-
neapolis, MN, USA) was applied for DNA extraction. Genotyping of
C-2399A SNP, described elsewhere,21 required the modification of
an allele-specific polymerase chain reaction assay.39
The SNP genotypes served two purposes: (1) to compare allele
and genotype frequencies between HSRþ and HSR patients; (2)
to evaluate associations between SNP genotypes and phenotypes
(APP activity or different kinetic parameters of BK and des-Arg9-
BK) in both groups (HSR and HSRþ ).
Pharmacological investigations
Production and purification of human recombinant soluble
membrane APP. A secreted form of wild-type human APP was
engineered and fully characterized.22
Inhibition studies of recombinant APP with metallopeptidase
inhibitors. Kinetics parameters were measured with GraphPad
Prism version 4.00 for Windows (GraphPad Software, San Diego,
CA, USA, www.graphpad.com). The data were plotted to fit the one-
site competition equation by nonlinear regression, with imposed
constraints (5.0 to 110% activities).
All enzyme activity assays were performed at 371C. Assay
mixtures minus recombinant APP served as controls. Stock
solutions of different inhibitors (ramipril, apstatin, enalapril,
captopril, and lisinopril) were successively diluted in N-2-hydro-
xyethylpiperazine-N0-2-ethanesulfonic acid 0.1 M (pH 7.4). The
final concentrations tested ranged from 0 to 1 or 10 mM. Reactions
were in triplicate and incubated at 371C for 90 min, with or without
a metallopeptidase inhibitor. Hydrolysis of the fluorogenic substrate
K(Dnp)PPGK(Abz) was performed as follows: reactions were in
150 ml volume in opti 96-well plates containing 100 mM N-2-
hydroxyethylpiperazine-N0-2-ethanesulfonic acid buffer (pH 7.4),
10 mM substrate, and purified recombinant enzymes. Fluorescence
was measured kinetically (every 5 min) with a FL600 microplate
fluorescence plate reader (BioTek, Winooski, VT, USA) with
excitation of 340 nm and an emission of 420 nm.
Statistical analysis. For kinetic parameters and enzyme
activities, the means of the parameters for the two groups (HSRþ
and HSR) were compared by t-test with the Satterthwaite-Welch
approach, taking into account the possible heterogeneity of
variances40 using SPSS, version 13.0. Po0.05 values were considered
statistically significant.
The heritability coefficients of APP and the different kinetic
parameters of kinins were calculated on z-scored values by SOLAR
(Sequential Oligogenic Linkage Analysis Routines, version 2.1.4
Official)41 with robust estimation of means and variance according
to t-distribution. Po0.05 values were considered statistically
significant.
The APP means were compared between the genotype groups by
one-way analysis of variance, followed by linear contrasts; a t-test
was used for the recessive genetic model.40 SNP association results
were statistically significant at Po0.001.
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